Daily Pharmacy News

Get your free subscription started now. Just enter your email address below.

Reduced Adverse COVID-19 Outcomes in Patients Taking Hypoglycemic Agents

Patients under treatment of diabetes with certain glucose-lowering agents have lower rates of adverse outcomes from COVID-19, according to a systematic review and network meta-analysis. Use of sodium-glucose cotransporter-2 inhibitors (SGLT-2is) was associated with lower COVID-19-related adverse outcomes, the authors report, as were glucagon-like peptide-1 receptor agonists and metformin.

A total of 31 observational studies of 3.7 million patients provided these insights into the association between a composite of COVID-19–related adverse outcomes (intensive care unit admission, invasive and noninvasive mechanical ventilation, or in-hospital death) and the use of 8 antihyperglycemic drugs in patients with diabetes: “[The SGLT-2is] were associated with relatively lower risks of adverse outcomes compared with insulin (log of odds ratio [logOR], 0.91; 95% credible interval [CrI], 0.57-1.26), dipeptidyl peptidase-4 inhibitors (logOR, 0.61; 95% CrI, 0.28-0.93), secretagogues (logOR, 0.37; 95% CrI, 0.02-0.72), and glucosidase inhibitors (logOR, 0.50; 95% CrI, 0.00-1.01). Based on the surface under the cumulative ranking curves value, SGLT-2is were associated with the lowest probability for adverse outcomes (6%), followed by glucagon-like peptide-1 receptor agonists (25%) and metformin (28%). A sensitivity analysis revealed that the study was reliable.”

Source: JAMA Network Open